Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Verdecchia, Paolo ^a   Angeli, Fabio ^b   Lip, Gregory Y H ^c   Reboldi, Gianpaolo ^d  

^a Hospital of Assisi   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT; PLACEBO; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; VITAMIN K GROUP;

ARTICLE; BLEEDING RISK; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN PROTECTION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EMBOLISM PREVENTION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; META ANALYSIS (TOPIC); ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS AS TOPIC; FACTOR XA INHIBITORS; HUMANS; META-ANALYSIS AS TOPIC; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; STROKE; THIAZOLES; THIOPHENES; VITAMIN K; WARFARIN;

EID: 84903542650     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100478     Document Type: Article

References (48)

1. Hart RG, Pearce LA, Aguilar MI (2007) Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 147: 590-592. (Pubitemid 351664513)
2. Husted S, De Caterina R, Andreotti F, Arnesen H, Bachmann F, et al. (2014) Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 111:781-782.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992.
6. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, et al. (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369: 2093-2104.
7. Beasley BN, Unger EF, Temple R (2011) Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 364: 1788-1790.
8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, et al. (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33: 2719-2747.
9. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, et al. (2012) Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e531S-575S.
10. Lip GY, Larsen TB, Skjoth F, Rasmussen LH (2012) Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 60: 738-746.
11. Rasmussen LH, Larsen TB, Graungaard T, Skjoth F, Lip GY (2012) Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 345: e7097.
12. Baker WL, Phung OJ (2012) Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 5: 711-719.
13. Mantha S, Ansell J (2012) An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 108: 476-484.
14. Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, et al. (2012) Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 31: 330-339.
15. Sardar P, Chatterjee S, Wu WC, Lichstein E, Ghosh J, et al. (2013) New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One 8: e77694.
16. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, et al. (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 338: b1147.
17. Cannon CP, Kohli P (2012) Danger ahead: watch out for indirect comparisons! J Am Coll Cardiol 60: 747-748.
18. Harenberg J, Marx S, Wehling M (2012) Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next? Thromb Haemost 108: 407-409.
19. Skjoth F, Larsen TB, Rasmussen LH (2012) Indirect comparison studies - are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thromb Haemost 108: 405-406.
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
21. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L (2010) Newly identified events in the RE-LY trial. N Engl J Med 363: 1875-1876.
22. D'Agostino RB Sr, Massaro JM, Sullivan LM (2003) Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med 22: 169-186.
23. Durrleman S, Chaikin P (2003) The use of putative placebo in active control trials: two applications in a regulatory setting. Stat Med 22: 941-952. (Pubitemid 36322096)
24. Hasselblad V, Kong DF (2001) Statistical methods for comparison to placebo in active-control trials. Drug Info J 35: 435-439.
25. Kaul S, Diamond GA, Weintraub WS (2005) Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 46: 1986-1995. (Pubitemid 41713579)
26. James Hung HM, Wang SJ, Tsong Y, Lawrence J, O9Neil RT (2003) Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med 22: 213-225. (Pubitemid 36163582)
27. Snapinn SM (2004) Alternatives for discounting in the analysis of noninferiority trials. J Biopharm Stat 14: 263-273.
28. Lee S, Shafe AC, Cowie MR (2011) UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database. BMJ Open 1: e000269.
29. Connolly SJ, Eikelboom J, O9Donnell M, Pogue J, Yusuf S (2007) Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation 116: 449-455. (Pubitemid 47196550)
30. Snapinn S, Jiang Q (2011) Indirect comparisons in the comparative efficacy and non-inferiority settings. Pharm Stat 10: 420-426.
31. Snapinn S, Jiang Q (2008) Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Stat Med 27: 382-391. (Pubitemid 351227874)
32. Lip GY, Edwards SJ (2006) Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 118: 321-333. (Pubitemid 44067199)
33. Kistler JP (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 323: 1505-1511.
34. Koudstaal PJ (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342: 1255-1262.
35. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, et al. (1991) Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 18: 349-355.
36. McBride R (1991) Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84: 527-539.
37. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1: 175-179. (Pubitemid 19038801)
38. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, et al. (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327: 1406-1412.
39. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50: 683-691. (Pubitemid 27341818)
40. Edwards SJ, Clarke MJ, Wordsworth S, Borrill J (2009) Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract 63: 841-854.
41. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, et al. (2011) Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14: 429-437.
42. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, et al. (2011) Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14: 417-428.
43. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, et al. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870. (Pubitemid 32537350)
44. Oler A, Whooley MA, Oler J, Grady D (1996) Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 276: 811-815. (Pubitemid 26301581)
45. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, et al. (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100: 1593-1601.
46. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, et al. (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383: 955-962.
47. Skjoth F, Larsen TB, Rasmussen LH, Lip GY (2014) Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 111. Epub ahead of print.
48. Food and Drug Administration (2010) Guidance for Industry: Non-Inferiority Clinical Trials. Available: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf. Accessed 2 January 2014.